Prognostic Factors in First-Line Chemotherapy Treated Metastatic Gastric Cancer Patients: A Retrospective Study

Basit Öğe Kaydı
dc.contributor.authorInal, Ali
dc.contributor.authorKaplan, M. Ali
dc.contributor.authorKucukoner, Mehmet
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorGuven, Mehmet
dc.contributor.authorNas, Necip
dc.contributor.authorYunce, Muharrem
dc.date.accessioned2024-04-24T17:28:16Z
dc.date.available2024-04-24T17:28:16Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: The majority of patients with gastric cancer in developing countries present with advanced disease. Systemic chemotherapy therefore has limited impact on overall survival. Patients eligible for chemotherapy should be selected carefully. The aim of this study was to analyze prognostic factors for survival in advanced gastric cancer patients undergoing first-line palliative chemotherapy. Methods: We retrospectively reviewed 107 locally advanced or metastatic gastric cancer patients who were treated with docetaxel and cisplatin plus fluorouracil (DCF) as first-line treatment between June 2007 and August 2011. Twenty-eight potential prognostic variables were chosen for univariate and multivariate analyses. Results: Among the 28 variables of univariate analysis, nine variables were identified to have prognostic significance: performance status, histology, location of primary tumor, lung metastasis, peritoneum metastasis, ascites, hemoglobin, albumin, weight loss and bone metastasis. Multivariate analysis by Cox proportional hazard model, including nine prognostic significance factors evident in univariate analysis, revealed weight loss, histology, peritoneum metastasis, ascites and serum hemoglobin level to be independent variables. Conclusion: Performance status, weight loss, histology, peritoneum metastasis, ascites and serum hemoglobin level were identified as important prognostic factors in advanced gastric cancer patients. These findings may facilitate pretreatment prediction of survival and can be used for selecting patients for treatment.en_US
dc.identifier.doi10.7314/APJCP.2012.13.8.3869
dc.identifier.endpage3872en_US
dc.identifier.issn1513-7368
dc.identifier.issue8en_US
dc.identifier.pmid23098485
dc.identifier.scopus2-s2.0-84873621970
dc.identifier.scopusqualityQ3
dc.identifier.startpage3869en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2012.13.8.3869
dc.identifier.urihttps://hdl.handle.net/11468/20383
dc.identifier.volume13en_US
dc.identifier.wosWOS:000311459400056
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Prevention
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGastric Canceren_US
dc.subjectFirst-Line Chemotherapyen_US
dc.subjectPrognostic Factorsen_US
dc.titlePrognostic Factors in First-Line Chemotherapy Treated Metastatic Gastric Cancer Patients: A Retrospective Studyen_US
dc.titlePrognostic Factors in First-Line Chemotherapy Treated Metastatic Gastric Cancer Patients: A Retrospective Study
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu